(OT) Thanks, chart, I hadn't seen that. Sumit has identified Gainspeed as Vecima's biggest competitor in the Distributed Access space - a space that will have a TAM of $1 - 1.5 billion/year. This buyout, imo, validates Sumit's decision to go 'all in' on that architecture. The question is how well Vecima will compete with a division of yet another powerhouse hardware builder. If history is any guide, it will do quite well.
Nice to see ORBC adding another big customer. We'll see if the $9 area holds.
Threre is no way Vecima doesn't beat guidance big time for the 3rd qtr.
Guidance will need to be raised again for fiscal '16 from high C$108 million. The DVAP sales (C$16mil over next 2 qtrs.) added to core sales of C$25 -27 each push rev to annual C$120.
Most encouraging, though, is Sumit's reply to Todd Copland's question during the last CC about revenue after the DVAP contract fills: "We expect to be in a good position to remain where we're at."
So he believes Terrace will be strong enough to hold sales at that level until new products kick in during the 1st half of calendar 2017.
This is my largest position and I'm expecting a continued climb to higher stock price. Also holding your ORBC (thanks) , some MLNX calls - bought yesterday after the earnings smack down, INFN, NNVC (spec play), RSYS. Also threw a few shares of your GLUU into the port last month. If the market slips I'll expect these to hold up OK. We'll see.
175,000 shares at C$11.70. We know the 3 qtr. report will be very good, as will the 4th. The DVAP sales will pump $16mil.C into the top line over those qtrs. Profits will soar, cash will build and the PE will plummet. What's not to like! Oh, yeah, the stock price!
Yeah, ORBC is a keeper. Of course, now, I'd like a little sell off in order to load up. Thanks for that one.
RSYS and MLNX have also been strong lately. My most speculative play is NNVC. Very few drug candidates ever get near commercialization, but those that do can be huge.